Heart failure & cardiomyopathies
Contributors and Solutions to High Out-of-Pocket Costs for Heart Failure Medications: A State-of-the-Art Review
Study context
- Population
- Patients with HF facing out-of-pocket medication costs, US health care system as an illustrative example
- Outcome
- Contributors to and solutions for high OOP costs of HF medications
Main finding
As reported in the abstract
Upcoming US policy change: cap on out-of-pocket (OOP) drug spending for Medicare Part D Plans in 2025
$2,000
Original publication
Contributors and Solutions to High Out-of-Pocket Costs for Heart Failure Medications: A State-of-the-Art Review. J Am Coll Cardiol. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →